Antiplatelet Therapy Use Before PCI Declining

The timing of antiplatelet medication administration is changing in individuals undergoing cardiac procedures.

4:00 PM

Author | Shantell M. Kirkendoll

Doctors worried about dangerous blood clots in patients undergoing a coronary artery procedure— such as angioplasty to treat a heart attack — will often administer antiplatelet therapy to head off complications.

But pre-procedural use of antiplatelet agents P2Y12 inhibitors is becoming less routine, according to registry results presented by the University of Michigan Frankel Cardiovascular Center at EuroPCR, the European Association of Percutaneous Cardiovascular Interventions conference in Paris.

Over a 30-month period, the initial administration of P2Y12 inhibitors in the pre-procedural time period declined from 49.3 percent to 24.8 percent across a consortium of 47 Michigan hospitals.

More and more, patients are being administered the initial dose of P2Y12 inhibitor therapy during or after their procedure and patients remained protected against stent thrombosis, bleeding, the need for transfusion and death.

Researchers studied 74,053 patients undergoing PCI between January 2013 through June 2015 at hospitals that contribute data to the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). There were no significant differences in in-hospital outcomes between patients treated with pre-procedural P2Y12 inhibitors compared to those who were not treated with pre-procedural P2Y12 inhibitor therapy, the data showed.

Importantly, these findings remained consistent in the subgroup of patients undergoing PCI who presented with acute coronary syndrome, from unstable angina to STEMI.

The current approach of increasingly reserving the use of these drugs after the patient enters the cath lab appears to be as effective and safe as pre-procedural administration.
Hitinder Gurm, M.D.

Changes in P2Y12 inhibitor administration                              

Historically clopidogrel has been the most widely used P2Y12 inhibitor. Its limitations, such as response variability, are well known, however.

Partly due to these limitations, two new P2Y12 inhibitors, ticagrelor and prasugrel, were developed and have a faster onset of action and achieve higher levels of platelet inhibition than clopidogrel.

Of the 24,733 patients who received a pre-procedural P2Y12 inhibitor, data shows 82 percent received clopidogrel, 8 percent prasugrel and 10 percent ticagrelor.

The optimal timing of P2Y12 inhibitor administration relative to PCI remains a topic of continued research and ongoing debate, says Devraj Sukul, M.D., a University of Michigan cardiology fellow who presented the study in Paris.

As pre-procedural P2Y12 inhibitor use has declined, there was an increase in the initial administration of P2Y12 inhibitors in the intra- or post-procedural time periods from 48.8 percent in the first quarter of 2013 to 71.4 percent in the second quarter of 2015.

Interventional cardiologist Hitinder Gurm, M.D., associate chief of cardiovascular medicine at U-M, leads the BMC2 quality improvement registry that revealed the changing pattern in patient care.

"While more work is needed to determine the optimal timing in patients undergoing PCI, the current approach of increasingly reserving the use of these drugs after the patient enters the cath lab appears to be as effective and safe as pre-procedural administration," he says.


More Articles About:

Lab Report Cardiac Surgery Cardiovascular: Treatment & Surgery
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Green, teal and purple figures on a black chart needing different levels of opioids and one entering a red danger zone
Health Lab

Anxiety Among Patient Factors Linked to More Opioid Use After Surgery

New research from Michigan Medicine could help doctors identify which patients are more likely to continue opioids after surgery
Heart shaped blood bag for red blood cell transfusion
Health Lab

Model Helps Clinicians Predict Post-Cardiac Surgery Blood Transfusions

Model predicts the need for red blood cell transfusion after CABG surgery. See the preoperative variables associated with blood transfusion in CABG patients.
A man sits on a large red tractor. Behind him a bunch of corn is stacked in the back of the vehicle
Health Lab

Michigan man undergoes complex heart repair after last minute surgery cancelation

A complex operation at U-M Health enabled surgeons to remove scar tissue surrounding Scott Roach's heart and successfully repair his failing mitral valve.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
A smartphone displaying a red heart with a white EKG line on its screen, set against a teal background.
Health Lab

Mobile health app improves heart failure medication use, dosing after hospitalization

A U-M-led trial found a mobile app improved use and dosing of recommended heart failure medications during the 90 days following a hospital discharge.
Boy in white t-shirt, just chin showing, with hands holding a stethoscope on his chest.
Health Lab

Distance, insurance, social factors may hinder access to lifesaving heart monitoring for children

New research suggests that social, economic and geographic factors may influence whether patients who undergo the Fontan surgery for complex congenital heart disease receive the recommended lifelong cardiac monitoring.